黄葵胶囊联合环磷酰胺治疗难治性肾病综合征的临床效果研究

目的 探究黄葵胶囊联合环磷酰胺治疗难治性肾病综合征的临床效果.方法 整群选取该院2013年8月—2015年7月收治的62例难治性肾病综合征患者作为研究对象,采取随机数字表法将所有患者分为实验组(31例)和对照组(31例),所有患者予以常规西医治疗,对照组患者联合环磷酰胺静脉冲击疗法治疗,实验组患者联合环磷酰胺静脉冲击疗法及黄葵胶囊治疗,对比两组患者治疗效果、各项检测指标(24 h尿蛋白定量、白蛋白、尿素氮、肌酐)及不良反应情况. 结果 两组患者治疗后总有效率对比,实验组总有效率为96.77%,对照组为83.87%,实验组总有效率明显高于对照组,差异有统计学意义(P<0.05);两组患者各项检测指标对比,治疗后实验组24 h尿蛋白定量、白蛋白、尿素氮、肌酐均明显优于对照组,差异具有统计学意义(P<0.01);实验组治疗后出现1例恶心,总不良反应率为3.23%,对照组出现3例恶心,2例胃肠道反应,1例感染,总不良反应率为19.35%,实验组患者总不良反应率明显低于对照组,差异具有统计学意义(P<0.05). 结论 黄葵胶囊联合环磷酰胺静脉冲击疗法治疗难治性肾病综合征临床效果显著,可明显改善患者临床症状,促进患者康复,且不良反应少,安全可靠,具有较高临床应用及推广价值.

Clinical Effect of Ambrette Capsule Combined with Cyclophosphamide for the Treatment of Refractory Nephrotic Syndrome

Objective To explore the clinical effect of ambrette capsule combined with cyclophosphamide in the treatment of refractory nephrotic syndrome. Methods 62 cases with refractory nephrotic syndrome admitted in our hospital from Au-gust 2013 to July 2015 were selected as the subjects and randomly divided into the experimental group (31 cases) and con-trol group (31 cases) in accordance with the random number table method. Based on the conventional western medicine treatment, the control group were given cyclophosphamide intravenous pulse therapy, the experimental group were given cy-clophosphamide intravenous pulse therapy and ambrette capsule. The treatment effect, the levels of detection indicators (24h urinary protein, albumin, urea nitrogen and creatinine) and incidence of adverse reactions of the two groups were compared. Results The response rate was much higher in the experimental group than that in the control group (96.77% vs 83.87%) with statistically significant difference, P<0.05. The level of 24h urinary protein, albumin, urea nitrogen and creatinine was much better in the experimental group than that in the control group respectively, with statistically significant difference, P<0.01. After treatment, in the experimental group, nausea occurred in 1 case, in the control group, nausea occurred in 3 cas-es, gastrointestinal reactions occurred in 2 cases, infection occurred in 1 case, the overall incidence of adverse reactions was obviously lower in the experimental group than that in the control group(3.23%vs 19.35%), with statistically significant dif-ference, P<0.05. Conclusion For patients with refractory nephrotic syndrome, ambrette capsule combined with cyclophos-phamide intravenous pulse therapy is safe and reliable with remarkable effect, which can obviously improve the clinical symptoms, promote the recovery with less adverse reactions and high value of clinical application and popularization.